


HICOR

2018 ANNUAL REPORT

HUTCHINSON INSTITUTE FOR
CANCER OUTCOMES RESEARCH



From The Directors



Scott Ramsey
MD, Ph.D.

Director



Veena Shankaran
MD, MS

Co-Director



Gary Lyman
MD, MPH

*Senior Lead, Healthcare
Quality and Policy*

2018 marked a major milestone in HICOR's efforts to provide actionable metrics to improve cancer care in our community. In May, we released the Community Cancer Care in Washington State: Quality and Cost Report. This report is the first in the nation to publicly report clinic-level quality measures linked to cost in oncology, and its publication reflects a commitment among Washington state providers, payers, patients, and policymakers to collaboration and transparency in pursuit of better patient care.

In May, HICOR and Microsoft launched an innovative collaboration focused on reducing emergency room visits and hospitalizations for patients undergoing chemotherapy. This project was inspired by a HICOR community working group -composed of patients, providers and payers — who recognized the need for proactive and responsive tools to support patients in symptom management.

The HICOR scientific team continues to grow, with the addition of new faculty members Rachel Issaka, MD, MAS, Salene Jones, Ph.D., MA, and Parth Shah, PharmD, Ph.D. These outstanding investigators bring important expertise in disparities in care, patient-reported outcomes, and cancer screening and prevention.

As we begin a new year, we want to share changes in institute leadership. In January 2019, Dr. Veena Shankaran will step into the HICOR Co-Director role, and Dr. Lyman will take on a new role as HICOR Senior Lead, Healthcare Quality and Policy. Dr. Shankaran is a medical oncologist who specializes in caring for patients with gastrointestinal malignancies. Her research expertise includes health economics and comparative effectiveness research, with a focus on developing novel approaches to measure and mitigate financial burden for cancer patients. We are delighted to welcome Dr. Shankaran to the leadership team.

In closing, we express our sincere appreciation for Dr. Lyman's service and contributions as Co-Director since HICOR's inception. Dr. Lyman's national leadership in clinical oncology, guideline development, and policymaking have been essential to our growth and success, and we look forward to his continued contributions in his new role.

Scott Ramsey

Veena Shankaran

Welcome New Faculty

We are delighted to welcome Drs. Rachel Issaka, Salene Jones and Parth Shah to the scientific team. These outstanding clinicians share a strong commitment to understanding patient perspectives and incorporating them into their research portfolios.

Rachel Issaka
MD, MAS



Increasing Colorectal Cancer Screening and Reducing Disparities in Care

As a clinical gastroenterologist and health services researcher, my research focuses on increasing colorectal cancer screening rates, with a particular interest in factors that disproportionately impact minority and low-income populations. This interest was born out of observing low overall colorectal cancer screening rates among minority and low-income patients during my Internal Medicine training. My research focuses on identifying the facilitators of and barriers to successful colorectal cancer screening and cancer care to inform the implementation of interventions that improve colorectal cancer screening rates, reduce screening disparities, and improve survival along the cancer continuum for racially and socioeconomically diverse populations.

Salene M. W. Jones
Ph.D., MA, LP



Measuring the Patient Perspective

People with cancer often experience symptoms like anxiety and depression that can negatively impact their quality of life, treatment outcomes, and survivorship experience. As a clinical psychologist and psychometrician, I focus my research on developing reliable tools to measure patient-reported outcomes—such as financial anxiety and the financial consequences of cancer—so that all of a patient’s needs can be addressed. I also conduct research to understand how anxiety may affect healthcare choices, such as choosing doctors or therapies. I am inspired by the patients and families that I have seen in clinical practice, and my goal is to conduct research that impacts health policy and clinical oncology practice to better meet patients’ needs.

Parth Shah
PharmD, Ph.D.



Cancer Screening and Prevention in the Community

As a behavioral scientist and pharmacist, I focus my research on how pharmacies may be leveraged to provide cancer prevention and early detection services—such as HPV vaccinations and colorectal cancer screenings—in community settings. Pharmacies are in places where people live and go to work and are an opportune setting to increase our health systems’ capacity to provide important health services in accessible, convenient locations. This is especially important in historically disenfranchised communities—rural, low income, and certain racial minorities. My research goal is to identify facilitators of and barriers to effective pharmacy-based delivery of cancer care services, and to develop implementation models that can be scaled nationally.

BUILT TO ENGAGE

HICOR IQ

A single resource to be used by payers, providers, and researchers for information about quality and cost of cancer care



HICOR IQ combines Washington state cancer registry and health insurance data.

Features

- Create your own metrics
- Ability to filter
- Functionality to share reports with users in your clinic
- Medicare data to 2016
- Commercial payer data to 2017

Log in or sign up at

hicoriq.org

Select Publications

Bansal A, Sullivan SD, Hershman DL, **Lyman GH**, Barlow WE, McCune JS, **Ramsey SD**.

A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. *J Comp Eff Res*. 2017 Jul;6[5]:461-470.

Takahashi TA, **Lee CI**, Johnson KM. Breast cancer screening: Does tomosynthesis augment mammography? *Cleve Clin J Med*. 2017 Jul;84[7]:522-527.

Wong P, **Panattoni L**, Tai-Seale M. Features of patient-centered primary care and the use of ambulatory care. *Popul Health Manag*. 2017 Aug;20[4]:294-301.

Mewes JC, **Steuten LMG**, IJzerman MJ, van Harten WH. A systematic approach for assessing, in the absence of full evidence, whether multicomponent interventions can be more cost-effective than single component interventions. *Int J Technol Assess Health Care*. 2017 Sep; 11:1-10.

Lee JM, Ichikawa L, Valencia E, Miglioretti DL, Wernli K, Buist DSM, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD. Performance benchmarks for screening breast MR imaging in community practice. *Radiology*. 2017 Oct;285[1]:44-52.

McDermott CL, Fedorenko C, Kreizenbeck K, Sun Q, Smith B, Curtis JR, Conklin T, **Ramsey SD**. End-of-life services among patients with cancer: Evidence from cancer registry records linked with commercial health insurance claims. *J Oncol Pract*. 2017 Nov;13[11]:e889-e899.

Trister AD, Buist DSM, **Lee CI**. Will machine learning tip the balance in breast cancer screening? *JAMA Oncol*. 2017 Nov 1;3[11]:1463-1464.

Mewes JC, **Steuten LMG**, IJzerman MJ, van Harten WH. Value of implementation of strategies to increase the adherence of health professionals and cancer survivors to guideline-based physical exercise. *Value Health*. 2017 Dec;20[10]:1336-1344.

Select Publications

Luo J, Johnston BS, Kitsch AE, Hippe DS, Korde LA, Javid S, **Lee JM**, Peacock S, Lehman CD, Partridge SC, Rahbar H. Ductal carcinoma in situ: Quantitative preoperative breast MR imaging features associated with recurrence after treatment. *Radiology*. 2017 Dec;285[3]:788-797.

Houssami N, **Lee CI**, Buist DSM, Tao D. Artificial intelligence for breast cancer screening: Opportunity or hype? *Breast*. 2017 Dec;36:31-33.

Burnett-Hartman AN, Adams SV, **Bansal A**, McDougall JA, Cohen SA, Karnopp A, Warren-Mears V, **Ramsey SD**. Indian Health Service Care System and Cancer Stage in American Indians and Alaska Natives. *J Health Care Poor Underserved*. 2018;29[1]:245-252.

Buckley SA, Kirtane K, Walter RB, Lee SJ, **Lyman GH**. Patient-reported outcomes in acute myeloid leukemia: Where are we now? *Blood Rev*. 2018 Jan;32[1]:81-87.

Rios J, Gosain R, **Goulart BH**, Huang B, Oechsli MN, McDowell JK, Chen Q, Tucker T, Kloecker GH. Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. *Cancer Manag Res*. 2018 Jan 24;10:167-175.

de Ligt KM, Witteveen A, Siesling S, **Steuten LMG**. Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study. *BMC Cancer*. 2018 Jan 24;18[1]:96.

Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, **Ramsey S**, Schwartz N, Kreizenbeck K, Nelson J, Balch A, Singleton E, Gallagher K, Overstreet K. Pilot feasibility study of an oncology financial navigation program. *J Oncol Pract*. 2018 Feb;14[2]:e122-e129.

Panattoni L, Fedorenko C, Greenwood-Hickman MA, Kreizenbeck K, Walker JR, Martins R, Eaton KD, Rieke JW, Conklin T, Smith B, **Lyman G**, **Ramsey SD**. Characterizing potentially preventable cancer- and chronic disease-related emergency department use in the year after treatment initiation: A regional study. *J Oncol Pract*. 2018 Mar;14[3]:e176-e185.

Yezefski T, Steelquist J, Watabayashi K, Sherman D, **Shankaran V**. Impact of trained oncology financial navigators on patient out-of-pocket spending. *Am J Manag Care*. 2018 Mar;24[5 Suppl]:S74-S79.

Jones SMW, Walker R, Fujii M, Nekhlyudov L, Rabin BA, Chubak J. Financial difficulty, worry about affording care, and benefit finding in long-term survivors of cancer. *Psychooncology*. 2018 Apr;27[4]:1320-1326.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. *N Engl J Med*. 2018 May 24;378[21]:2036-2044.

Jones SMW, Salem R, Amtmann D. Somatic symptoms of depression and anxiety in people with multiple sclerosis. *Int J MS Care*. 2018 May-Jun;20[3]:145-152.

Deverka PA, Bangs R, Kreizenbeck K, Delaney DM, Hershman DL, Blanke CD, **Ramsey SD**. A new framework for patient engagement in cancer clinical trials cooperative group studies. *J Natl Cancer Inst*. 2018 Jun 1;110[6]:553-559.

Guerriero MK, Redman MW, Baker KK, Martins RG, Eaton K, Chow LQ, Santana-Davila R, Baik C, **Goulart BH**, Lee S, Rodriguez CP. Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. *Cancer*. 2018 Jul 1;124[13]:2841-2849.

Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ. A qualitative study exploring patient motivations for screening for lung cancer. *PLoS One*. 2018 Jul 5;13[7]:e0196758.

Issaka RB, Singh MH, Rachocki C, Day LW, Horton C, Somsouk M. Missed opportunities in colorectal cancer prevention in patients with inadequate bowel preparations. *Clin Gastroenterol Hepatol*. 2018 Sep;16[9]:1533-1534.

Lyman GH, Yau L, Nakov R, Krendyukov A. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. *Ann Oncol*. 2018 Sep 1;29[9]:1903-1910.

Alsayid M, Singh MH, **Issaka R**, Laleau V, Day L, Lee J, Allison J, Somsouk M. Yield of colonoscopy after a positive result from a fecal immunochemical test OC-Light. *Clin Gastroenterol Hepatol*. 2018 Oct;16[10]:1593-1597.

Yezefski T, Schwemm A, Lentz M, Hone K, **Shankaran V**. Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. *Semin Hematol*. 2018 Oct;55[4]:185-188.

Panattoni L, Chan A, Yang Y, Olson C, Tai-Seale M. Nudging physicians and patients with autopend clinical decision support to improve diabetes management. *Am J Manag Care*. 2018 Oct;24[10]:479-483.

Flowers CR, **Ramsey SD**. What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia? *J Clin Oncol*. 2018 Oct 2; JCO2018793570.

Issaka RB, Avila P, Whitaker E, Bent S, Somsouk M. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review. *Prev Med*. 2018 Oct 24;118:113-121.

McDermott CL, **Bansal A**, **Ramsey SD**, **Lyman GH**, Sullivan SD. Depression and health care utilization at end of life among older adults with advanced non-small-cell Lung Cancer. *J Pain Symptom Manage*. 2018 Nov;56[5]:699-708.e1.

Margolis MA, Brewer NT, **Shah PD**, Calo WA, Gilkey MB. Stories about HPV vaccine in social media, traditional media, and conversations. *Prev Med*. 2018 Nov 7;118:251-256.

Doll KM, Khor S, Odem-Davis K, He H, Wolff EM, Flum DR, **Ramsey SD**, Goff BA. Role of bleeding recognition and evaluation in Black-White disparities in endometrial cancer. *Am J Obstet Gynecol*. 2018 Dec;219[6]:593.e1-593.e14.

Roth JA, Sullivan SD, Lin VW, **Bansal A**, Purdum AG, Navale L, Cheng P, **Ramsey SD**. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. *J Med Econ*. 2018 Dec;21[12]:1238-1245.

VALUE IN CANCER CARE SUMMIT

HICOR catalyzed discussions among regional stakeholders about data transparency and the improvement of cancer care delivery by hosting the 5th Annual Value in Cancer Care Summit and publicly releasing the Community Cancer Care in Washington State: Quality and Cost Report.

2018 Summit: Making Measurement Matter

Over 200 providers, patients and patient advocates, payers, health system representatives, researchers and students convened at the 5th Annual HICOR Value in Cancer Care Summit on May 3, 2018 at Bell Harbor International Conference Center in Seattle to discuss “making measurement matter” in oncology.

This year’s conference centered on national trends and opportunities in performance measurement, the importance of data transparency and public reporting, and strategies for driving improvement in cancer care delivery. To learn more about the Value in Cancer Care Summit presentations and interactive discussions, visit www.fredhutch.org/vccsummit.



Patient advocates Diane Mapes [left] and Bridgette Hempstead discuss metrics that matter to cancer patients.



Dr. Eve Kerr, with the University of Michigan, speaks about using performance measurements to motivate change during the Value in Cancer Care Summit at the Bell Harbor International Conference Center in Seattle, Washington on May 3, 2018.

“The time is right to advance performance measurement that promotes high-value, patient-centered care”

— Eve Kerr

Director, Ann Arbor
VA Center for Clinical
Management Research;
University of Michigan

PHOTOS BY ROBERT HOOD

(LEFT) Dr. Gary Gilliland, left, chats with a participant during a break at the Value in Cancer Care Summit.

(RIGHT & NEXT PAGE) Participants engage during a break at the Value in Cancer Care Summit at the Bell Harbor International Conference Center in Seattle, Washington on May 3, 2018.



VALUE IN CANCER CARE SUMMIT

HICOR catalyzed discussions among regional stakeholders about data transparency and the improvement of cancer care delivery by hosting the 5th Annual Value in Cancer Care Summit and publicly releasing the Community Cancer Care in Washington State: Quality and Cost Report.

Inaugural Community Cancer Care Report

The Community Cancer Care in Washington State: Quality and Cost Report 2018 is the first publicly accessible statewide report showing clinic-level quality measures linked to cost in cancer care.

The results presented in this report draw from a patient-level database that links enrollment and claims records from commercial and public health insurance plans with clinical information from Washington state cancer registries, including approximately 70 percent of their cancer patients who received care in Washington state between 2014 and 2016.

Quality measures prioritized by our community stakeholders include: recommended treatment immediately following diagnosis, emergency department and inpatient hospital admissions during treatment, appropriate use of surveillance testing for patients who have been treated with curative intent, and care for patients in the last 30 days of life.

We believe that quality reporting is an important step towards achieving health care's triple aim — better health, better care and lower costs — and that sharing the data publicly will spur collaboration, research, and innovation.



Graphs from the Community Cancer Care Report

Key Findings

Nearly 86 percent of breast, colorectal, and lung cancer patients in the population measured receive recommended treatments based on guidelines in a timely fashion.

Over half [52.0%] of cancer patients have an emergency department visit or require hospitalization during their first six months of chemotherapy treatment.

At end of life, the use of hospice is variable, and many patients spend time in the intensive care unit instead of at home or in lower-intensity settings.



To learn more about the report, visit www.fredhutch.org/cancer-care-report.



Partnering with Microsoft to Tackle Side Effect Management

A 2017 study lead by HICOR Sr. Staff Scientist Dr. Laura Panattoni found that more than half of Washington state cancer patients undergoing chemotherapy are hospitalized or treated in the emergency department - many for symptoms such as nausea, pain, fever, and fatigue. Patients and families experiencing treatment-related crises spend hours or sometimes days in emergency departments that are often ill-equipped to deal with oncologic emergencies. Unplanned emergency department visits and inpatient stays contribute to poor patient experience and increasing costs of care, and expose immunocompromised patients to risk of infection.

It was Dr. Panattoni's hope that seeing this data would promote innovative thinking and investment in how oncology teams manage patient symptoms.


"Managing nausea, pain, dehydration, diarrhea, and other symptoms in an outpatient setting has great potential to improve patient experience and decrease the cost of care."

—Dr. Laura Panattoni

Building on these findings, HICOR and Microsoft have launched a project to evaluate a smartphone application and third-party biosensor aimed at supporting chemotherapy patients through home symptom tracking and management. The collaboration will leverage HICOR expertise in oncology analytics, health economics, research, and trial design together with Microsoft technology development capabilities to create solutions for this critically important area in cancer care.

"The idea is to identify patients who are getting into trouble early, so oncology clinics can treat their symptoms before they reach crisis levels."

—Dr. Scott Ramsey



HICOR and Microsoft will work together to build and test a new technology platform that provides clinicians with real-time biometric and patient-reported information to identify and intervene with patients before adverse effects reach critical levels.

Providing patients with the means to report their symptoms and vital status to their providers during treatment is a potentially transformative approach to improving patient experience and care quality.

Faculty Members



Aastha Bansal, Ph.D., MS

Assistant Professor, UW
Assistant Member, Fred Hutch/UW
Statistical Methods for Biomarker-Guided
Decision-Making | Prediction Modeling |
Treatment Sequencing | Comparative
Effectiveness Research

abansal@uw.edu



Bernardo Goulart, MD, MS

Associate Professor, UW
Joint Assistant Member, Fred Hutch/UW
Attending Physician, SCCA
Thoracic and Head and Neck Malignancies
| Cancer Outcomes Research and Health
Economic Evaluations

bgoulart@fredhutch.org



Rachel Issaka, MD, MS

Assistant Member, Clinical Research & Public
Health Sciences Divisions, Fred Hutch
Assistant Professor, Internal Medicine, UW
Colorectal Cancer Screening | Healthcare
Disparities and Outcomes Research | Population
Health | Comparative Effectiveness Research

rissaka@fredhutch.org



Salene Jones, Ph.D., MA

Assistant Member, Fred Hutch
Survey and Questionnaire Development |
Patient-Reported Outcomes | Mental Health
and Quality of Life in Cancer Survivors |
Psychometrics

smjones3@fredhutch.org



Christoph Lee, MD, MS

Professor, Radiology, UW | Adjunct Professor,
Health Services, UW | Radiologist, SCCA | Affiliate
Investigator, HICOR

Breast Cancer Screening | Comparative
Effectiveness Research | Imaging Technology
Assessment

stophlee@uw.edu



Janie M. Lee, MD, MSc

Associate Professor, Radiology, UW Section
Chief, Breast Imaging, UWMC | Director of Breast
Imaging, SCCA | Affiliate Investigator, HICOR

Breast Cancer Screening | Surveillance, Imaging
Technology Performance and Outcomes
Assessment

jmlee@seattlecca.org



Laura Panattoni, Ph.D.

Senior Staff Scientist, Fred Hutch
Cancer Care Delivery Research | Performance
Measurement | Implementation Costs | Health
Economics

lpnanatto@fredhutch.org



Joshua Roth, Ph.D., MHA

Assistant Member, Fred Hutch
Affiliate Assistant Professor, UW
Simulation Modeling | Lung Cancer
Screening | Economic Evaluation | Cancer
Pharmacogenomics | Patterns of Care

jroth@fredhutch.org



Parth Shah, PharmD, Ph.D.

Assistant Member, Fred Hutch
Health Behavior and Behavioral Medicine |
Health Services Research | Implementation
Science | Pharmacy | Cancer Prevention and
Control

pshah@fredhutch.org



Lotte Steuten, Ph.D., MSc

Associate Member, Fred Hutch
Associate Affiliate Professor, UW
Comparative Effectiveness Research |
Economic Evaluation | Decision Analytic
Modeling | Value of Information Research

lsteuten@fredhutch.org

External Advisory Board

The EAB is charged with providing guidance on HICOR's broad scientific agenda and strategic direction.




Dana Goldman, Ph.D., Chair

Director's Chair, Leonard D. Schaeffer for Health Policy and Economics; Professor of Public Policy and Pharmacy, University of Southern California



Thomas W. Feeley, MD

Senior Fellow, Institute of Strategy and Competitiveness, Harvard Business School



Peter Bach, MD, MAAP

Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center



Jennifer Malin, MD, Ph.D.

Senior Medical Director, Oncology and Genetics, UnitedHealth Group



Alan Balch, Ph.D., MS

CEO, Patient Advocate Foundation and National Patient Advocate Foundation



Arnold Milstein, MD, MPH

Professor of Medicine
Clinical Excellence Research Center Director;
Stanford University School of Medicine



Diana Brixner, Ph.D., RPh

Professor, Department of Pharmacotherapy; Executive Director, Outcomes Research Center, College of Pharmacy, University of Utah



Peter Neupert, MBA

Advisor and board member of public and private companies in the health sector



Craig Earle, MD, MSc, FRCP[C]

Vice President, Cancer Control, Canadian Partnership Against Cancer



Barry Straube, MD

Former Chief Medical Officer, Centers for Medicare and Medicaid Services [CMS]



Peter Yu, MD

Physician-in-Chief, Hartford HealthCare Cancer Institute

HICOR Team



Photo by Robert Hood / Fred Hutch

FROM LEFT TO RIGHT, BACK ROW: Kat Egan, Veena Shankaran, Sarah Barger, Haven Wilvich, Rachel Issaka, Scott Ramsey, Bernardo Goulart, Jordan Steelquist. SECOND ROW: Ari Bell-Brown, Julia Walker, Laura Panattoni, Shasank Chennupati, Qin Sun, Karma Kreizenbeck. FRONT ROW: Gary Lyman, Catherine Fedorenko, Kate Watabayashi, Debbie Delaney, Lily Li, Kristy Drury, Judy Nelson, Annika Ittes, Andrea Tate. NOT PICTURED: Aasthaa Bansal, Yuxian Du, Salene Jones, Christoph Lee, Janie Lee, Trung Nguyen, Josh Roth, Parth Shah, Lotte Steuten.



FRED HUTCH

FRED HUTCHINSON CANCER RESEARCH CENTER
1100 Fairview Avenue N. · Seattle, WA 98109



fredhutch.org